ARCA Biopharma, Inc.
http://www.arcabiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ARCA Biopharma, Inc.
Oruka Aiming At AbbVie, UCB In Psoriatic Indications
The third Paragon spinout, going public in a reverse-merger with ARCA, announced a concurrent $275m financing to help it develop optimized biologics as potential standards of care in psoriasis and psoriatic arthritis.
Pipeline Watch: Phase III Progress With Semaglutide, Tecentriq And Epidaza
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch Phase III Starts With IMO-2125, VX-659, And Tralokinumab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Amazon Versus Biotech: How The IPO Class Of '97 Worked Out
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Pharmacogenetics-Pharmacogenomics
- Other Names / Subsidiaries
-
- Nuvelo, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice